Updated:
LianBio
LianBio is a company founded in 2020 in Shanghai, Shanghai. It focuses on developing medicines for cardiorenal diseases and oncology. LianBio collaborates with...
LianBio
LianBio is a company founded in 2020 in Shanghai, Shanghai. It focuses on developing medicines for cardiorenal diseases and oncology. LianBio collaborates with partners to advance programs with scientific basis and clinical data.
General information
Firm type
Asset Manager
Year founded
2019
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Additional offices
Princeton, New Jersey, United States
Principals
Yizhe Wang
Chief Executive Officer
Deborah Yu
Chief Financial Officer
Sector focus
Frequently asked questions
Which sectors does LianBio explicitly avoid?
LianBio does not publicly disclose excluded sectors, but its disclosed pipeline focuses on cardiovascular, oncology, and inflammatory disease therapeutics — areas with large Asian patient populations and regulatory pathways established by prior approvals.
Does LianBio participate in fund commitments or only direct deals?
LianBio operates through direct licensing and co-development arrangements with other biotechnology companies. It does not manage external fund commitments; its capital is raised through private equity rounds from institutional investors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: